Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Activist FDA Could Benefit Drug Development

This article was originally published in RPM Report

Executive Summary

Former FDA Commissioner David Kessler sees a big opportunity for FDA to clarify approval criteria for cancer drugs and personalized medicine projects in the period after the upcoming election. This is time to begin planning for that period of opportunity.
Advertisement

Related Content

Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama
No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama
Who Should Be The Next FDA Commissioner? David Kessler Weighs In
FDA Commissioner Search: Myths And Reality
Chart: Who's On First: A Preliminary List FDA Commissioner Candidates
FDA Commissioner Says Funding Imperils Agency Mission, Modernization
The Next Steps for Personalized Health Care: Incentivizing Product Development
A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS080406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel